Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Leases (2016 - 2025)

Vistagen Therapeutics' Current Leases history spans 12 years, with the latest figure at $617000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 2.32% year-over-year to $617000.0; the TTM value through Dec 2025 reached $617000.0, up 2.32%, while the annual FY2025 figure was $561000.0, 2.0% up from the prior year.
  • Current Leases for Q4 2025 was $617000.0 at Vistagen Therapeutics, up from $597000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $640000.0 in Q2 2025 and bottomed at $300.0 in Q4 2021.
  • The 4-year median for Current Leases is $525000.0 (2024), against an average of $371420.0.
  • The largest annual shift saw Current Leases plummeted 99.91% in 2021 before it soared 31636.84% in 2024.
  • A 4-year view of Current Leases shows it stood at $300.0 in 2021, then soared by 533.33% to $1900.0 in 2023, then skyrocketed by 31636.84% to $603000.0 in 2024, then grew by 2.32% to $617000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Current Leases are $617000.0 (Q4 2025), $597000.0 (Q3 2025), and $640000.0 (Q2 2025).